George Rieveschl, Inventor of Benadryl, Dies
CINCINNATIUniversity of Cincinnati (UC) alumnus and engineering professor emeritus George Rieveschl, PhD, known for inventing Benadryl, the worlds first effective antihistamine, died today at Christ Hospital, Cincinnati. He was 91.
A long-time supporter of the
Dr. Rieveschl was also the founding chairman of the University Foundation Board of Trustees.
Rieveschl was a chemistry professor at UC when he invented Benadryl.
He found to this surprise that a two-part compound he was originally testing to improve muscle-relaxing medications dramatically blocked histamine, the naturally released chemical that narrows air passages in the lungs and causes inflammation.
This breakthrough led, in 1946, to Benadryls becoming the first FDA-approved prescription antihistamine. First produced by Parke, Davis and Company, the drug is now distributed over-the-counter by the Parke-Davis division of Pfizer.
A 1937 alumnus of UC, Dr. Rieveschl spent 26 years working in the chemical industry as both a scientist and a consultant before returning to UC in 1970.
He is survived by his wife, Ellen, and two sons.
George Rieveschl, PhD
Jane Henney, MD, presents Benadryl inventor George Rieveschl, PhD, with a city proclamation noting May 16 as "60 Years of Benadryl" day.
Related Stories
Travel, tattoos & vaccine truths: Clearing up blood donation myths
February 3, 2026
In recent years, the U.S. Food and Drug Administration (FDA) has updated several blood donation deferrals and restrictions. Despite these changes, many myths and misconceptions persist about who can and cannot donate safely.
UC study: New treatment guidelines needed for chronic kidney disease patients
February 3, 2026
A recently published study from the University of Cincinnati College of Medicine emphasizes the need for new treatment guidelines in the U.S. on reproductive health among patients with chronic kidney disease (CKD).
Cancer Center tests treatment using ‘glioblastoma-on-a-chip’ and wafer technology
February 3, 2026
A multidisciplinary team of University of Cincinnati Cancer Center researchers has received a $40,000 Ride Cincinnati grant to study the use of a delayed release preparation or wafer of an immunostimulatory molecule known as IL-15 to stimulate the central nervous system immune system after surgery to remove glioblastoma brain tumors.